PhaseBio Pharmaceuticals Inc

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp on January 10, 2002 and is headquartered in Dover, DE.

PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code

Akero Therapeutics Inc

Applied DNA Sciences

Avenue Therapeutics

HeartBeam

Immuneering Corp

Mind Medicine MindMed

Shuttle Pharmaceuticals Holdings Inc

Spero Therapeutics

Virios Therapeutics

September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -3.03% and 91.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

PhaseBio Pharmaceuticals (PHAS) Reports Q2 Loss, Lags Revenue Estimates

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

PhaseBio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Recent Business Highlights

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of 65.67% and 98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

PhaseBio Pharmaceuticals (PHAS) Reports Q1 Loss, Misses Revenue Estimates

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the first quarter ended March 31, 2022, and provided an update on corporate activities. “The first quarter of 2022 was a period of significant momentum for PhaseBio, as we continued to advance our pipeline and lay the groundwork for

PhaseBio Pharmaceuticals Reports First Quarter 2022 Financial Results and Recent Business Highlights

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab

PhaseBio Announces Successful Pre-BLA Meeting with U.S. FDA for Bentracimab

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference

PhaseBio Pharmaceuticals to Participate in the 21st Annual Needham Healthcare Conference

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab

PhaseBio Announces Positive Results from Phase 2b Trial for Bentracimab

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Bentracimab--PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

PhaseBio Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business Highlights

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update

PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference

PhaseBio Pharmaceuticals to Participate in the Cowen 42nd Annual Health Care Conference

MALVERN, PA & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #ACC22--PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at 2022 ACC Annual Scientific Session

PhaseBio Announces Bentracimab Phase 2b Trial Data Accepted for Late Breaking Clinical Research Presentation at the 2022 American College of Cardiology (ACC.22) Annual Scientific Session

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) is voluntarily ending its Phase 2b trial of pemziviptadil (PB1046) in pulmonary arterial hypertension (PAH). The decision follows COVID-19 impacts on manufacturing, associated drug supply, and enrollment rate in the study.

PhaseBio Pulls Plug On Mid-Stage Hypertension Asset

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Provides Pemziviptadil (PB1046) Program Update

PhaseBio Provides Pemziviptadil (PB1046) Program Update

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #NEJM--PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence

PhaseBio Announces Publication of Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab in NEJM Evidence

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Names Jonathan Birchall as Chief Commercial Officer

PhaseBio Names Jonathan Birchall as Chief Commercial Officer

PhaseBio's (PHAS) phase III study evaluating bentracimab for the reversal of antiplatelet effects of ticagrelor meets primary endpoint. The stock falls on high rates of the drug's side effects.

PhaseBio (PHAS) Dips on Mixed Data From Antiplatelet Drug Study

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced interim results from the REVERSE-IT Phase 3 trial of bentracimab to reverse the antiplatelet effects of ticagrelor. The trial included patients with urgent surgery or an invasive procedure or experiencing uncontrolled major or life-threatening bleeding.

PhaseBio's Shares Slide As Antiplatelet Candidate Shows Higher Rates Of Side Effect

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor

PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Urgent Surgery or Experiencing Uncontrolled Major or Life-Threatening Bleeding

PhaseBio Pharmaceuticals (PHAS) delivered earnings and revenue surprises of -6.45% and -87.43%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

PhaseBio Pharmaceuticals (PHAS) Reports Q3 Loss, Lags Revenue Estimates

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights

PhaseBio Reports Third-Quarter 2021 Financial Results and Recent Business Highlights

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #AHA2021--PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at AHA Annual Meeting

PhaseBio Pharmaceuticals to Host Investor Call to Discuss Interim Results from Pivotal REVERSE-IT Phase 3 Trial Presented at the American Heart Association Annual Meeting

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has announced topline data from its Phase 2b trial of bentracimab in healthy, older volunteers 50-80 years old. The trial in 150 subjects receiving bentracimab and 50 subjects receiving placebo after all were pretreated with dual antiplatelet therapy composed of AstraZeneca Plc's (NASDAQ: AZN) Brilinta (ticagrelor) and low-dose aspirin.

PhaseBio's Bentracimab Reverses Ticagrelor-Associated Antiplatelet Activity In Mid-Stage Study

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Announces Topline Results from Phase 2b Trial for Bentracimab

News for PhaseBio Pharmaceuticals Inc Stock (PHAS)